Get started
Author

Claudio Brescia

Observed name: Claudio BRESCIA
ORCID: 0009-0007-5094-5052
Observed ORCID: 0009-0007-5094-5052
OpenAlex ID: A5096743808
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
2024 · Luca Potestio, Cataldo Patruno, et al. · Journal of Asthma and Allergy · 11
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
2024 · Matteo Megna, Angelo Ruggiero, et al. · Clinical Cosmetic and Investigational Dermatology · 11
PDF
Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies
2025 · Giuseppe Lauletta, Cataldo Patruno, et al. · Antibodies · 9
PDF
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use
2025 · Matteo Megna, Giuseppe Lauletta, et al. · Expert Opinion on Biological Therapy · 9
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis)
2025 · Luca Potestio, Cataldo Patruno, et al. · Archives of Dermatological Research · 9
PDF
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature
2024 · Fabrizio Martora, Nello Tommasino, et al. · Medicina · 5
PDF
The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients
2024 · Cataldo Patruno, Luca Potestio, et al. · Journal of the European Academy of Dermatology and Venereology · 5
PDF
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
2025 · Luca Potestio, Fabrizio Martora, et al. · Dermatology and Therapy · 4
PDF
The efficacy of dupilumab in patients affected by atopic dermatitis who previously failed tralokinumab
2024 · Luca Potestio, Claudio Brescia, et al. · International Journal of Dermatology · 2
PDF
A 52‐Week Retrospective Italian Study of Flare Characteristics in Adult Atopic Dermatitis Patients Receiving JAK Inhibitors
2026 · Claudio Brescia, Carolina D'Elia, et al. · International Journal of Dermatology · 1
Evaluation of an Artificial Intelligence-Assisted Videodermoscopy System for Cutaneous Lesion Classification: A Retrospective Study
2026 · Antonia Salsano, Luisa Di Costanzo, et al. · Dermatology Practical & Conceptual
Cumulative Life Course Impairment in Atopic Dermatitis: A Comprehensive Review
2026 · Claudio Brescia, Chiara Palagiano, et al. · Medical Sciences
Pharmacotherapeutic strategies for the treatment of severe juvenile acne
2026 · Chiara Palagiano, Luca Potestio, et al. · Expert Opinion on Pharmacotherapy
Effectiveness of Baricitinib in Treating Atopic Dermatitis in Difficult-to-treat Areas: A Retrospective Real-world Study
2026 · Giuseppe Lauletta, Maddalena Napolitano, et al. · Acta Dermato Venereologica
PDF
Minimal disease activity in atopic dermatitis: a 24-week real-life comparison of JAK inhibitors
2026 · Luca POTESTIO, Claudio BRESCIA, et al. · Italian Journal of Dermatology and Venereology
Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data
2026 · Fabrizio Martora, Nello Tommasino, et al. · Medicina
Rigenase® and PHMB-based Formulations for the Management of Diverse Cutaneous Lesions: Results from a National Post-Marketing Clinical Follow-up (PMCF) Survey
2026 · Antonio Miracapillo, Claudio Brescia, et al. · Journal of Surgery
PDF
West Nile virus: a diagnostic challenge for dermatologists
2026 · Claudio BRESCIA, Maddalena NAPOLITANO, et al. · Italian Journal of Dermatology and Venereology
Allergic Contact Dermatitis From a Polyester Trouser Mimicking Atopic Dermatitis
2025 · Claudio Brescia, Luca Potestio, et al. · Contact Dermatitis
Works count: 19
Citation count: 65
H-index: 5
I10-index: 2
Year
Topic
Type